Multicenter Study to Evaluate the Procedural Safety and Efficacy of ELCA in CAD (ELCA-CAD)

• ClinicalTrials.gov Identifier: NCT03284229
• Recruitment Status: Completed
• First Posted: September 15, 2017
• Results First Posted: September 18, 2020
• Last Update Posted: September 18, 2020
• Sponsor: Spectranetics Corporation
• Collaborator: CBCC-VIBGYOR Research Pvt. Ltd.
• Information provided by (Responsible Party): Spectranetics Corporation

Study Description

Brief Summary:

This is a Prospective, Open label, Non-randomized, Single-Arm, Multicenter Study to Evaluate the Procedural Safety and Efficacy of ELCA® in Treatment of Patients with Single or Multivessel Coronary Artery Disease (CAD). Up to 30 patients will be enrolled at up to 05 Indian study sites. Patients will be followed from enrollment through 30 days ± 7 days for the effectiveness and safety endpoints at the study centre.

Condition or disease	Intervention/treatment	Phase
Coronary Artery Disease	Device: Excimer Laser Coronary Atherectomy	Not Applicable

Detailed Description:

Each subject will be followed from enrollment through 30 days ± 7 days for the effectiveness and safety endpoints. Upon enrollment after obtaining a written informed consent, each patient will be assigned a unique identification number. Only patients eligible to undergo cardiac catheterizations as per routine practice will be considered for the study. Premedication of patients will be as per the investigator's routine practice. All patient data will be recorded on patient data forms.

Screening: This will be performed prior to the cardiac catheterization procedure. Only patients who have consented and fulfill the selection criteria will be enrolled. Additionally, ECG and Echocardiogram will be done using hospital equipment to ensure fulfillment of inclusion/exclusion criteria.

Procedure: The entire procedure will be carried out as per the site routine practice and the device will be used as per the IFU.

Clinic follow up visit (30 ± 7 days): The subject will return to the clinic at 1 month to evaluate angina status as per the CCS classification, AE assessments, concomitant medications and any coronary intervention that has occurred since the previous contact.

An electrocardiogram (ECG) will be repeated during the clinic visit.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 28 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Intervention Model Description: As per the 25th SEC (Cardiovascular & Renal) meeting which deliberated the proposals on 30-10-2015 and recommended the firm (Spectranetics Corporation - Sponsor) shall conduct a Bridging study in Indian Population at least 25 patients with coronary artery disease. The directorate suggested that the sponsor submit a protocol for the study in India for clinical trial approval. Considering the 5 dropouts, Sponsor has set up this protocol to conduct the Excimer Laser Coronary Atherectomy (ELCA®) study in India on 30 eligible patients across 05 sites as a Stand-alone modality or in conjunction with Percutaneous Transluminal Coronary Balloon Angioplasty (PTCA) in single or multi-vessel coronary artery disease.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Prospective, Open Label, Non-randomized, Single-Arm, Multicenter Study to Evaluate the Procedural Safety and Efficacy of ELCA® in Treatment of Patients With Single or Multivessel Coronary Artery Disease (CAD)
• Actual Study Start Date: September 20, 2017
• Actual Primary Completion Date: May 21, 2018
• Actual Study Completion Date: May 21, 2018

Arms and Interventions

Arm

Intervention/treatment

Experimental: Excimer Laser Coronary Atherectomy; ELCA® in patients with single or multivessel CAD either as a stand-alone modality or in conjunction with Percutaneous Transluminal Coronary Balloon Angioplasty (PTCA). The entire procedure will be carried out as per the site routine practice and the device will be used as per the 'Instruction for Use'. Treating physicians/study investigators will be trained by the study Sponsor on the study protocol and procedures prior to clinical investigation procedure. Subject preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted.

Device: Excimer Laser Coronary Atherectomy; Excimer Laser Coronary Atherectomy (ELCA ®) uses the high energy, monochromatic light beam to alter or dissolve (vaporize) the plaque without damaging the surrounding tissue. Fiber-optic catheters are used to deliver this light beam. For endovascular applications, Xenon Chloride excimer laser is used and its fiber-optic catheter has multiple small fibers, rather than just a few large fibers, in order to be flexible enough to navigate in the arterial tree.; Other Name: ELCA Coronary Laser Atherectomy Catheters (OTW and RX)

Outcome Measures

Primary Outcome Measures :

1. Participants With Device Success During Procedure Defined as the Successful Crossing of the Laser Catheter Across the Entire Length of the Stenotic Lesion [ Time Frame: Procedure ]
   Successful crossing of the Laser Catheter across the entire length of the stenotic lesion
2. Participants With Procedural Success Defined as Target Lesions With Less Than 50% Residual Stenosis After Laser and Adjunctive Therapy During Procedure [ Time Frame: Procedure ]
   Target lesions with less than 50% residual stenosis after laser and adjunctive therapy.
3. Safety Success - Participants With Freedom From Major Adverse Cardiac Events (MACE) Defined as Death, Non-Q-wave and Q-wave Myocardial Infarction (MI), Target Lesion Revascularization, Cardiac Tamponade and Life Threatening Arrhythmias [ Time Frame: 30 days ]
   Freedom from Major Adverse Cardiac Events (MACE) defined as Death, Non-Q-wave and Q-wave myocardial infarction (MI), Target Lesion Revascularization, Cardiac tamponade and life threatening arrhythmias.

Secondary Outcome Measures :

1. TIMI Flow [ Time Frame: pre-procedure and post-procedure ]

   To determine post-procedural TIMI Flow grade. Changes of TIMI Grade flow after Index Procedure by measuring pre-procedure TIMI grade flow and post-procedure TIMI grade flow.

   TIMI flow is a scoring system from 0-3 referring to levels of coronary blood flow assessed during percutaneous coronary angioplasty. TIMI flow was assessed before and after the procedure. TIMI grade flow 0-3 are as described below.

   • TIMI 0 flow (no perfusion) refers to the absence of any antegrade flow beyond a coronary occlusion.
   • TIMI 1 flow (penetration without perfusion) is faint antegrade coronary flow beyond the occlusion, with incomplete filling of the distal coronary bed.
   • TIMI 2 flow (partial reperfusion) is delayed or sluggish antegrade flow with complete filling of the distal territory.
   • TIMI 3 is normal flow which fills the distal coronary bed completely.
2. Lesion Morphology - Coronary Tortuosity Based on Degree of Tortuosity [ Time Frame: Procedure ]
   Tortuosity from coronary angiography
3. Lesion Morphology - Eccentricity of Coronary Lesion [ Time Frame: Procedure ]
   Eccentricity from coronary angiography as concentric (symmetric) or eccentric (asymmetric)
4. Lesion Morphology - Contour as a Lesion Characteristic [ Time Frame: Procedure ]
   Contour from coronary angiography
5. Lesion Morphology - Bifurcation (Branch or Division of Artery) [ Time Frame: Procedure ]
   Bifurcation from coronary angiography
6. Participants With Device-related Complications During Procedure [ Time Frame: Procedure ]
   To determine device related complications
7. Participants With Procedure-related Complications During Procedure [ Time Frame: Procedure ]
   To determine procedure related complications

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Have at least one severely stenotic lesion (greater than or equal to 80% diameter stenosis as assessed by visual estimation)
• Haemodynamically stable patients coming to the site for cardiac catheterization and angiography for various indications and who fulfill all the following criteria:
• Have no clinically significant cardiac arrhythmias, based on ECG results
• Have no evidence of valvular pathology, based on echocardiogram results
• Have ≥30% left ventricular ejection fraction (LVEF), based on echocardiogram results.
• Angiographic evidence of calcification or a chronic total occlusion
• Vessel reference diameter greater than or equal to 2.0 mm
• Patient is willing and able to comply with study requirements
• Women of child bearing potential, willing to use at least two methods of contraception

Exclusion Criteria:

• Evidence of acute coronary syndrome within 3 months prior to index procedure
• Evidence of acute ischemic events
• Cardiogenic and non-cardiogenic shock
• Active bleeding or coagulopathy
• Previous coronary angioplasty within 6 months of the index procedure
• Patients participating in trial for another investigational device/medicine within 1 month prior to enrolment in this study
• Acute or Chronic renal failure, Impaired renal function (serum creatinine > 2.5 mg/dl or 221 umol/l) determined within 72 hours prior to index procedure.
• Known allergies to the following: Aspirin, Clopidogrel or Ticlopidine, Heparin, Sirolimus or its derivatives, contrast agent (that cannot be adequately pre-medicated), or any metal
• Planned surgery within 6 months of enrollment in this study
• Life expectancy less than 6 months
• Patients known to be suffering from substance abuse (alcohol or drug)
• Patients with any other significant co-morbid illness which in the opinion of the investigator is not conducive of inclusion in the study.
• Known or suspected Pregnancy
• Patients not willing to provide written informed consent
• In the investigators opinion subjects will not be able to comply with the follow-up requirements.

Contacts and Locations

Locations

India

Escorts Heart Institute & Research Centre Limited

New Delhi, Delhi, India, 160011

All Indian Institute of Medical Sciences (AIIMS)

New Delhi, Delhi, India

Global Health Private Limited, Medanta - The Medicity

Gurgaon, Haryana, India, 122001

Sri Jayadeva Institute of Cardiovascular Sciences and Research

Bangalore, Karnataka, India, 560069

Lilavati Hospital and Research Centre

Bandra, Mumbai, India, 100050

Sponsors and Collaborators

Spectranetics Corporation

CBCC-VIBGYOR Research Pvt. Ltd.

Investigators

• Study Director: Karen Krygier, MBA; Spectranetics Corporation

  Study Documents (Full-Text)

Documents provided by Spectranetics Corporation:

Study Protocol  [PDF] October 12, 2016

No Statistical Analysis Plan (SAP) exists for this study.

More Information

Additional Information:

ELCA laser system and catheter IFUs 

• Responsible Party: Spectranetics Corporation
• ClinicalTrials.gov Identifier: NCT03284229
• Other Study ID Numbers: ELCA-1016
• First Posted: September 15, 2017
• Results First Posted: September 18, 2020
• Last Update Posted: September 18, 2020
• Last Verified: July 2020

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Spectranetics Corporation:

ELCA; Coronary Artery Disease; India

Additional relevant MeSH terms:

Coronary Artery Disease; Myocardial Ischemia; Coronary Disease; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases